COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?

Exp Clin Endocrinol Diabetes. 2022 Mar;130(3):198-199. doi: 10.1055/a-1235-5617. Epub 2020 Sep 10.

Abstract

Novel coronavirus infectious disease (COVID-19) has been recognised as a pandemic by the World Health Organization (WHO) 1. Mortality and morbidity are higher in elderly individuals and those with comorbidities, such as diabetes mellitus (DM), obesity, hypertension, respiratory tract diseases, coronary heart disease or cancer 1. Indeed, two thirds of individuals who died from COVID-19 had DM in Italy 2.

MeSH terms

  • Aged
  • COVID-19*
  • Communicable Diseases*
  • Diabetes Mellitus, Type 2* / drug therapy
  • Diabetes Mellitus, Type 2* / epidemiology
  • Glucose
  • Humans
  • Sodium
  • Sodium-Glucose Transporter 2 Inhibitors* / pharmacology

Substances

  • Sodium-Glucose Transporter 2 Inhibitors
  • Sodium
  • Glucose